Basket | Login | Register


Science watch


Our science watch section reports on the story behind the media-reported “breakthrough” headlines in dementia, by focusing on the original journal study. Reports of other developments in research on care and cure are also included.

25/03/2020 Clinical study shows no benefit of low-dose aspirin for risk reduction of dementia, mild cognitive impairment or cognitive decline
20/03/2020 Axsome Therapeutics accelerates the completion of its ADVANCE-1 trial of AXS-05 in AD agitation
18/03/2020 Critical Path Institute and H.Lundbeck A/S announce data sharing collaboration to advance drug discovery research for Alzheimer’s disease
16/03/2020 Study suggests link between inflammation in the brain and frontotemporal dementia
04/03/2020 Study investigates association between specific combinations of drugs and Alzheimer’s dementia risk
02/03/2020 Two studies published in Nature Medicine show the diagnostic value of blood tests for pTau181 in Alzheimer’s disease
27/02/2020 Biogen and Sangamo announce collaboration to develop gene regulation therapies for AD
26/02/2020 Study examines Dutch centenarians who maintained high levels of cognitive performance
25/02/2020 Biogen has a dedicated website about its Alzheimer’s drug candidate
13/02/2020 Annovis Bio is set to continue its Phase II DISCOVER trial of ANVS401 in AD
11/02/2020 Alzheimer’s Research UK announces launch of global digital diagnostics initiative, EDoN
10/02/2020 Investigational AD drugs solanezumab and gantenerumab fail to meet its primary endpoint in DIAN-TU Phase II/III study
04/02/2020 Researchers investigate the outcomes of a passive monitoring device in people with dementia and their carers
03/02/2020 Clinical study shows that possession of two APOE2 alleles confers substantial protection against Alzheimer’s dementia
03/02/2020 Merck has received approval from the FDA to expand indication for suvorexant for the treatment of insomnia in people with mild to moderate AD dementia